In fact, circulating adducts between hemoglobin and NAPQI have been detected, indicating some NAPQI even escapes hepatocytes, diffuses into RBCs, and combines with hemoglobin during its short existence
[3] [4] [6] [14] [9] The goal is not to create fear around an effective class of medications
Moreover, lixisenatide is a short-acting GLP-1RA with a half-life of ~3 h, suggesting an estimated daily engagement of GLP-1 receptors (GLP-1R) of ~14 h that could have possibly hampered the detection of its protective effects [10]
Glutathione is a natural reservoir of reducing power, which can be quick- ly used by the cells as defense against oxidative stress
Based on our data, we believe that the RESILIENCE trial would have achieved better outcome for the patients if it were designed to treat HR+ patients with Sorafenib together with hormonal therapy versus Placebo with hormonal therapy